Results 251 to 260 of about 306,457 (292)

Cinéma d’animation : « Le conte de fées est à l’aise au Moyen Âge »

, 2007
Michel Ocelot, Sandra Gorgievski
openalex   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

Arthritis &Rheumatology, Accepted Article.
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami, Francesco Pollastri, Angelo Fassio, Filippo Montanari, Anna Piccinelli, Camilla Benini, Emma Pasetto, Carmen Dartizio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana   +10 more
wiley   +1 more source

Health facilities readiness and associated factors to provide growth monitoring services in low-income and middle-income countries: evidence from national service provision assessment surveys of six countries. [PDF]

BMJ Open
Assefa DT, Belete NK, Gebretsadik MK.
europepmc   +1 more source

13 étoiles: reflets du Valais = Wallis im Bild [PDF]

, 2015

core  

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

Arthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, The TULIP‐SC investigators   +12 more
wiley   +1 more source

Health status in patients with limited health literacy; development and validity of the Clinical COPD Questionnaire graphic (CCQg). [PDF]

NPJ Prim Care Respir Med
Tiel Groenestege E, Sloothaak B, van Geer-Postmus I, van de Maat A, van Heijst E, van Reenen NH, Kan K, Kerkhof M, Lentjes C, van der Molen T, Zonneveld M, In 't Veen J, Kocks J.   +12 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Hospital finances following Connecticut's ban on outpatient facility fees. [PDF]

Health Aff Sch
Braun RT, Fernandez RJ, Swindle R, Monahan CH, Williams D.   +4 more
europepmc   +1 more source

More on the interstratification illusion : hystory of research, stratigraphy and dating of the grotte des Fées (Chatelperron).

, 2007
Joào Zilhão, Francesco d’Errico, Jean‐Guillaume Bordes, Arnaud Lenoble, Pierre-Jean Texier, Jean‐Philippe Rigaud   +5 more
openalex   +1 more source

Measuring the Impact: MRI Response of Sacroiliac Joints to TNF Inhibitors in Youth with Axial Disease

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes in youth with axial juvenile spondyloarthritis (axJSpA) initiating TNF inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source